Clinical Trials Logo

Clinical Trial Summary

Primary Objective: - To assess the immune response of the 3 SP0202 formulations, Prevnar 13 and Pneumovax 23 30 days after the administration of the single dose vaccination - To assess the safety profile of the 3 SP0202 formulations, Prevnar 13 and Pneumovax 23


Clinical Trial Description

The duration of each participant's participation will be approximately 6 months. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04583618
Study type Interventional
Source Sanofi
Contact
Status Completed
Phase Phase 2
Start date October 8, 2020
Completion date January 20, 2022